Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekFierceBiotech ↗
With a panel of outside experts set to weigh in Thursday-and with a refusal-to-file fiasco with the FDA just b…
The WeekBriefing
Starting next month, Medicare will offer weight loss drug coverage through a temporary program that observers …
The WeekDrug Channels ↗
By Bryce Platt, PharmD Summer officially starts this weekend! Consider doing a few of your lifting sets (or wo…
The WeekBioPharma Dive ↗
Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing "anti…
The WeekSTAT News ↗
Should the federal government try to slow - or even block - U.S. biotech deals that could benefit China?…
The WeekAJMC ↗
HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD…
The WeekPharmaVoice ↗
It's like "Rituxan all over again," said CEO Richard Miller who believes Corvus' lead candidate could make an …
The WeekFiercePharma ↗
Following criticism from drugmakers, Germany has scrapped its plan to install a program that would have reduce…
The WeekFierceBiotech ↗
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients' Robart's Histopathology…
The WeekBriefing
The FDA approved Colorado’s proposal to import certain Canadian drugs, aiming to curb costs for state resident…
The WeekBriefing
FDA approval expands Merck's Welireg and Keytruda pairing into adjuvant renal cell carcinoma, following Welire…
The WeekDrug Channels ↗
By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple…
The WeekDrug Channels ↗
By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple…
The WeekSTAT News ↗
As the Human Cell Atlas project marks its 10th anniversary, a leader's ties to a major single-cell RNA sequenc…
The WeekAJMC ↗
ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity…
The WeekBioPharma Dive ↗
For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous …
The WeekFiercePharma ↗
Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squib…
The WeekFierceBiotech ↗
Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another roun…
The WeekBriefing
Eli Lilly, Biogen, Eisai, and Genentech sponsor a new Alzheimer’s-focused podcast as pharma marketing leans de…
The WeekBioPharma Dive ↗
For sterile injectables, key early decisions can have a significant impact on the products' development.…
The WeekSTAT News ↗
Medicaid cuts and fraud crackdown trickle down to states, threatening people with disabilities.…
The WeekFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
The WeekFierceBiotech ↗
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
The WeekBriefing
STAT News spotlighted obesity drugs in development, peptide therapies going mainstream, and a record biotech I…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.